{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:04:43Z","timestamp":1759334683853,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jfo.2021.07.017","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:45:02Z","timestamp":1642596302000},"page":"e205-e207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Permanent bilateral mydriasis after treatment with nivolumab\/ipilimumab for cutaneous melanoma"],"prefix":"10.1016","volume":"45","author":[{"given":"F.","family":"Urbinati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zamorano Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rachwani Anil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Guti\u00e9rrez Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda Lorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mataix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Espa\u00f1a Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2021.07.017_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jfo.2021.07.017_bib0060","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jamaophthalmol.2019.2451","article-title":"Bilateral mydriasis and serous retinal detachments associated with ipilimumab and 6-melanoma helper peptide vaccine for cutaneous melanoma","volume":"137","author":"Rodriguez","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2021.07.017_bib0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ICU.0000000000000005","article-title":"A diagnostic challenge: Dilated pupil","volume":"24","author":"Caglayan","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2021.07.017_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.wno.0000235564.50518.1b","article-title":"Pupil abnormalities in selected autonomic neuropathies","volume":"26","author":"Bremner","year":"2006","journal-title":"J Neuro-Ophthalmol"},{"key":"10.1016\/j.jfo.2021.07.017_bib0075","series-title":"Hoyt's Clinical Neuro-Ophthalmology: The Essentials","first-page":"299","article-title":"Disorders of pupillary function, accommodation, and lacrimation","author":"Miller","year":"2008"},{"key":"10.1016\/j.jfo.2021.07.017_bib0080","series-title":"Neuro-ophthalmology. The requisites in ophthalmology","first-page":"191","article-title":"The pupil","author":"Martin","year":"2001"},{"key":"10.1016\/j.jfo.2021.07.017_bib0085","unstructured":"Opdivo\u00ae (nivolumab) injection, prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (2018)."},{"key":"10.1016\/j.jfo.2021.07.017_bib0090","unstructured":"Yervoy\u00ae (ipilimumab) injection, prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (2018)."},{"key":"10.1016\/j.jfo.2021.07.017_bib0095","first-page":"1","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","volume":"00","author":"Sun","year":"2020","journal-title":"Neuro-Ophthalmol"},{"key":"10.1016\/j.jfo.2021.07.017_bib0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CJI.0000000000000167","article-title":"Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: An unusual presentation of a rare complication of immunotherapy","volume":"40","author":"Wu","year":"2017","journal-title":"J Immunother"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551222000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551222000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:18:11Z","timestamp":1759259891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551222000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0181551222000092"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2021.07.017","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Permanent bilateral mydriasis after treatment with nivolumab\/ipilimumab for cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2021.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}